Platelet glycoprotein llb-llla

Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein llb/llla receptor blockade by a chimeric monoclonal antibody on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction (EPIC). Am J Cardiol 1996 77 1045-1051. [Pg.83]

Table 4 Randomized clinical trials of platelet glycoprotein llb/llla inhibitors during reperfusion therapy for acute ST-elevation myocardial infarction...

Lefkovits J, Plow EE Topol EJ. Platelet glycoprotein llb/llla receptors in cardiovascular medicine. N Engl J Med 1995 332 1553-1559. [Pg.55]

Lincoff MA, Califf RM, Topol EJ. Platelet glycoprotein llb/llla inhibitors in coronary artery disease. J Am Coll Cardiol 2000 284 1549-1558. [Pg.55]

Bhatt DL, Topol EJ. Current role of platelet glycoprotein llb/llla inhibitors in acute coronary syndromes. JAMA 2000 35 1 103-1 I 15. [Pg.55]

The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein llb/llla receptor in high-risk angioplasty. N Engl J Med 1994 330 956-961. [Pg.55]

The RESTORE Investigators. Effects of platelet glycoprotein llb/llla blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 1997 96 1445-1453. [Pg.55]

I I The EPILOG Investigators. Platelet glycoprotein llb/llla receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997 ... [Pg.55]

The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein llb/llla receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 338 1488-1497. [Pg.55]

The PURSUIT Trial Investigators. Investigators. Inhibition of platelet glycoprotein llb/llla with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998 339 436-443. [Pg.55]

The PAFfAGON Investigators. International, randomised, controlled trial of lamifiban (a platelet glycoprotein llb/llla inhibitor), heparin, or both in unstable angina. Circulation 1998 97 2386-395. [Pg.55]

Boersma E, Harrington R, Moliterno D, et al, Platelet glycoprotein llb/llla inhibitors in acute coronary syndromes A meta-analysis of all major randomised clinical trials, Lancet 2002 359 189-198. [Pg.56]

Chew DR Moliterno DJ. A critical appraisal of platelet glycoprotein llb/llla inhibition, J Am Coll Cardiol 2000 36 2028-2035. [Pg.56]

Boersma E, Akkerhuis KM, Theroux P et al, Platelet glycoprotein llb/llla receptor inhibition in non-ST-elevation acute coronary syndromes early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999 100 2045-2048. [Pg.56]

Topol EJ, Mark DB, Lincoff MA, etal. Outcomes at I year and economic implications of platelet glycoprotein llb/llla blockade in patients undergoing coronary stenting Results from a multicenter randomized trial, Lancet 1999 354 2019-2024. [Pg.56]

Topol EJ, Moliterno DJ, Herrmann HC, etal, Comparison of two platelet glycoprotein llb/llla inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001 344 1 888-1894. [Pg.56]

Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein llb/llla integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997 95 846. [Pg.56]

Montalescot G, Barragan FJ Wittenberg O, et al., for the ADMIRAL Investigators. Platelet glycoprotein llb/llla inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001 344 1895. [Pg.57]

Topol EJ, Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein llb/llla inhibition the GUSTO V randomized trial. Lancet 2001 357 1 905,... [Pg.57]

Efficacy and safety oftenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001 358 605. LincoffAM, Califf RM, Van De WerfE etal. Mortality at I year with combination platelet glycoprotein llb/llla inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction GUSTO V randomized trial. JAMA 2002 288 2130. [Pg.57]

Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein llb/llla blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes, J Invasive Cardiol 2000 I2(suppl E) E5-E9 discussion E25-E28,... [Pg.57]

Lincoff AM, Califf RM, Moliterno DJ, et al, Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein llb/llla receptors. New Engl J Med 1999 341 319-327. [Pg.58]

O Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein llb/llla integrin blockade with eptifibatide in coronary stent intervention, JAMA 2002 287 618. [Pg.58]

Kong DR Hasselblad V Harrington RA, et al. Meta-analysis of survival with platelet glycoprotein llb/llla antagonists for percutaneous coronary interventions. Am J Cardiol 2003 92 651-655. [Pg.58]

Kim W, Jeong MH, Hong YJ, et al. The long-term clinical results of a platelet glycoprotein llb/llla receptor blocker (Abciximab Reopro) coated stent in patients with coronary artery disease, Korean J Intern Med 2004 I 9(4) 220-229,... [Pg.260]

Aggarwal R, Ireland D, Azrin M, Ezekowitz M, De Bono D, Gershlick A, Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein llb/llla receptor antibody. Circulation 1996 94 331 1-3317. [Pg.263]

Chan AW, YadavJS, Bhatt DL, et al. Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein llb/llla inhibition during carotid stenting. Am J Cardiol 2005 95 791-795. [Pg.566]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...